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Abstract
Background: There is much interest in confirming whether the efficacy of abiraterone acetate (AA) demonstrated
within the trial setting is reproducible in routine clinical practice. We report the clinical outcome of metastatic
castration-resistant prostate cancer (mCRPC) patients treated with AA in real-life clinical practice.
Methods: The clinical records of mCRPC patients treated with AA from all 6 public oncology centers in Hong Kong
between August 2011 and December 2014 were reviewed. The treatment efficacy and its determinants, and toxicities
were determined.
Results: A total of 110 patients with mCRPC were treated with AA in the review period, of whom 58 were chemo-naive
and 52 had received prior chemotherapy (post-chemo). The median follow-up time was 7.5/11.4 months for chemo-
naive/post-chemo patients. 6.9/15.4 % of chemo-naive/post-chemo patients had visceral metastases. The median overall
survival (OS) and progression-free survival (PFS) were 18.1/15.5 months and 6.7/6.4 months for chemo-naive/post-chemo
patients, respectively. Among chemo-naive patients, those with visceral diseases had significantly inferior OS (2.8 vs 18.0
p = 0.0007) and PFS (2.8 vs 6.8 months, p = 0.0088) than those without. Pain control was comparable in both groups of
patients. The most common grade 3 or above toxicities were hypertension (6.9/5.8 %) and hypokalemia (3.4/3.8 %) in
chemo-naive/post-chemo patients. In multivariate analysis, the presence of prostate-specific antigen (PSA) response
(≥50 % drop of PSA from baseline) within the first 3 months of therapy was associated with favorable OS and PFS in
both chemo-naive and post-chemo group.
Conclusions: In clinical practice outside the trial setting, OS after AA in our chemo-naive patient cohort (18.1 months)
was considerably shorter than that reported in the COU-AA-302 trial (34.7 months), and the OS was particularly short
in those with visceral metastases (2.8 months). Conversely, AA was efficacious in post-chemo patients. AA resulted in
comparable pain control in both groups of patients. The presence of PSA response within the first 3 months of treatment
was a significant determinant of survival.
Keywords: Castration-resistant prostate cancer, Abiraterone acetate, Chemo-naïve, Chemotherapy, PSA response
* Correspondence: mc_poon@clo.cuhk.edu.hk
1Department of Clinical Oncology, State Key Laboratory in Oncology in
South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and
Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong,
Hong Kong
7Hong Kong Society of Uro-Oncology (HKSUO), Hong Kong, Hong Kong
Full list of author information is available at the end of the article
© 2016 Poon et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Poon et al. BMC Urology  (2016) 16:12 
DOI 10.1186/s12894-016-0132-z
Background
Androgen deprivation therapy (ADT), either medical or
surgical, is the backbone of first line treatment for meta-
static prostate cancer [1]. While up to 80 % of patients
will respond favorably to this therapy; metastatic
castration-resistant disease (mCRPC), would be encoun-
tered ultimately [2].
Since 2004, docetaxel chemotherapy was the standard
of care for patients with mCRPC [3, 4]. More recently,
the treatment paradigm had been altered dramatically
with the advent of several androgen receptor (AR) path-
way targeted agents, new-generation chemotherapy, and
immunotherapy [5]. Abiraterone acetate (AA), a potent
and irreversible inhibitor of cytochrome-P (CYP)-17 that
blocks androgen synthesis, has been shown in large-
scale randomized trials to confer significant survival
advantage over placebo in both chemo-naïve mCRPC
patients and mCRPC patients with prior chemotherapy
(post-chemo) [6, 7].
There is much interest in confirming whether the effi-
cacy of AA demonstrated within the trial setting is re-
producible in routine clinical practice, in consideration
of possible differences in selection of patients, ethnic
differences, and other factors in day-to-day practice. In
fact, for the case of docetaxel for mCRPC patients, pre-
vious retrospective studies had shown unexpectedly
higher incidence of febrile neutropenia and less favorable
survival outcome compared to that in the trial setting
[8, 9]. In the present study, we report on the clinical
outcome of AA in patients with mCRPC from all 6
public oncology centers in Hong Kong.
Methods
Ethics statement
The study was approved by the institutional review
board of the authors’ institutions (Joint Chinese Univer-
sity of Hong Kong – New Territories East Cluster Clin-
ical Research Ethics Committee/Ref no: CRE-2015.481).
And permission to access the medical records through
the inter-hospital computer network was granted by the
aforementioned review board. Furthermore, the princi-
ples of the Helsinki Declaration were followed. Informed
consent has been exempted by the review board as most
of the patients in this study were dead when the data
was collected.
Study population and treatment
In early 2011, AA was approved by the local health au-
thority for use in patients with mCRPC who had re-
ceived prior chemotherapy, and subsequently in 2012,
also for chemo-naïve patients. The present review in-
cluded mCRPC patients who were started on AA in 6
oncology centers between August 2011 and December
2014. All patients had metastatic prostate cancer which
had progressed despite achieving castration-level of tes-
tosterone. Enzalutamide, another AR pathway targeted
agent, was not accessible during the study period and
only be commercially available since October 2015 in
our locality [10]. Patients with visceral disease who were
medically unfit for, or who declined, chemotherapy, and
treated with AA within the period were also included.
Patients were treated with 1 g AA once daily in combin-
ation with 5 mg prednisone twice a day until disease
progression, death or unacceptable toxicity. Clinical and
biochemical follow-up with serum prostate-specific anti-
gen (PSA), blood counts, liver and renal profile were
regularly undertaken during the treatment period. Serum
lactate dehydrogenase (LDH) was not a mandatory par-
ameter to be regularly examined during the treatment.
Regular imaging assessment was not mandatory unless
clinical suspicion or biochemical progression was evi-
dent. Continuation of AA beyond disease progression
and post-AA treatments were at the discretion of in-
dividual oncologists based on several factors including
patient’s preference, medical condition or affordability,
physician’s preference and availability of alternative
treatment options.
Data collection and outcomes measures
The electronic clinical records of the patient cohort were
retrieved by the inter-hospital computer network. The
definition of clinical, biochemical and radiological pro-
gressive disease was according to the Prostate Cancer
Clinical Trials Working Group (PCWG-2) criteria [11].
Overall survival (OS) and progression-free survival (PFS)
were defined as time from first dose of AA to death, and
to the first event of clinical, radiographic or PSA pro-
gression or death, respectively. Patients who had transi-
ent serum PSA level upsurge but not to the extent of
biochemical progression (PCWG-2 criteria) followed by
a drop, were defined as having PSA flare. PSA doubling
time (PSA-DT) was calculated by determining the re-
gression slope of the log PSA against time based on 3
consecutive PSA measurements prior to AA. Patients
who had reduction or withdrawal of WHO class II or III
analgesics according to the WHO analgesics ladder dur-
ing or after AA was regarded as having improvement in
pain control. Treatment-related toxicities were graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE) 4.02
toxicity scale.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (Windows version
17.0.1.80; SPSS Inc, Chicago, US). The updated database
as at 1 May 2015 was used for analysis. Kaplan-Meier
plots of OS and PFS were obtained for subsets of
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patients segregated by various potential prognosticators.
The log-rank test was employed to assess the difference
in outcome between subsets. The variables were also
subject to multivariate analyses using the Cox propor-
tional hazards regression model. P values ≤ 0.05 were
considered significant. The hazard ratio (HR) and the
corresponding 95 % confidence interval were calculated.
Results
Characteristics of patients
Hundred and ten patients were reviewed, of whom 58
were chemo-naïve and 52 were post-chemo. Table 1
summarizes the characteristics of the patient cohort.
The median follow-up duration was 7.5 (range, 1.0–
24.6) and 11.43 (range, 1.2–30.2) months for chemo-
naïve and post-chemo group respectively. Visceral dis-
eases (non-nodal soft tissue metastases) were present in
4 (6.9 %) chemo-naïve and 8 (15.4 %) post-chemo pa-
tients. About 30 % of patients were symptomatic prior
the initiation of AA.
Clinical efficacy
PSA response
The proportion of patients with PSA response (in about
half of patients), PSA flare (about 30 % of patients), and
eventual response after PSA flare (about two-thirds of
patients with flare) were similar between the chemo-
naïve and post-chemo groups (Table 2). All of the PSA
response was present within the first 3 months of AA.
Duration of AA treatment and post-AA treatment
The median duration of AA treatment was 6.8 (range,
0.6–21.5) and 7.1 (0.5–25.0) months for chemo-naïve
and post-chemo group respectively, with 27 chemo-
naïve, and 13 post-chemo patients still under treatment
at the time of last follow-up. Disease progression was
the major reason of treatment discontinuation (Table 2).
Continuation of AA treatment beyond disease progres-
sion and post-AA treatments were observed in 13/18
and 7/11 chemo-naïve/post-chemo group respectively.
Overall survival and progression-free survival
The median OS was 18.1 (95 % confidence interval (CI):
9.9–25) and 15.5 (95 % CI: 13.8–23.6) months for
chemo-naïve and post-chemo group respectively (Fig. 1)
whereas their respective median PFS was 6.7 (95 % CI:
4.5–14.7) and 6.4 (95 % CI: 5.4–8.3) months (Fig. 2).
Chemo-naïve patients with visceral disease had signifi-
cantly inferior OS and PFS than those without (OS, 2.8
vs 18.0 months, p = 0.0007, HR: 6.907, 95 % CI: 1.81–
25.36; PFS, 2.8 vs 6.8 months, p = 0.0088, HR: 1.79, 95 %
CI: 0.73–4.42). In contrast, the differences in OS and
PFS were not significant between patients with or with-
out visceral disease in the post-chemo group (Fig. 3).








≥75 (%) 37 (63.8) 11 (21.2)
ECOG performance status, No. (%)
0–1 36 (62.1) 45 (86.5)
2 18 (31.0) 7 (13.5)
3 4 (6.9) 0
4 0 0
Gleason score at time of initial diagnosis
(%)
<8 24 (41.4) 19 (36.5)
≥8 16 (27.6) 29 (55.8)
Unknown 18 (31.0) 4 (7.7)








Symptomatic at presentationa, No. (%) 19 (32.8) 16 (30.8)
Baseline Hb (g/dl), median (range) 12 (5.2–15.5) 11.7
(5.7–14.9)




Disease location, No. (%)
Bone only 35 (60.3) 28 (53.8)
Bone 55 (94.8) 50 (96.2)
Lymph node 22 (37.9) 20 (38.5)
Lung 2 (3.4)b 3 (5.8)
Liver 3 (5.2)b 5 (9.6)
Co-morbidities, No (%)
Diabetes Mellitus 16 (27.6) 8 (15.4)
Hypertension 32 (55.2) 20 (38.5)
Hyperlipidemia 0 4 (7.7)
Atrial fibrillation 1 (1.7) 1 (1.9)
Congestive heart failure 1 (1.7) 0
No. of previous cytotoxic regimen (%)
1 0 44 (84.6)
2 0 7 (13.5)
3 0 1 (1.9)
Disease progression prior AA (%)
Biochemical progression only 42 (72.4) 35 (67.3)
Clinical or radiographic progression 16 (27.6) 17 (32.7)
Abbreviations: ECOG Eastern Cooperative Oncology Group, PSA prostate specific
antigen, Hb hemoglobin, ALP alkaline phosphatase, AA abiraterone acetate
apresence of pain prior abiraterone acetate and require WHO level II or
above analgesics
bOne patient with both liver and lung metastases
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Pain control
Improvement in pain control was observed in more than
half of the patients (Table 2).
Adverse events
Table 3 shows the treatment-related toxicities in patients
treated with AA. In chemo-naïve group, hypokalemia
(3.4 %), hypertension (6.9 %) and peripheral edema
(5.2 %) were the commonest grade 3 complications,
whereas hypertension (5.8 %), hypokalemia (3.8 %) and
elevation of liver enzymes (1.9 %) were the commonest
grade 3 toxicities in post-chemo group. There was no
grade 4 toxicity or treatment-related death among them.
Univariate and multivariate analysis
Chemo-naïve group
In univariate analysis, 6 variables, including the presence
of visceral disease (HR 6.907, 95 % CI 1.881–25.357,
p = 0.0007), were significantly determinants of the OS
(Table 4). In multivariate analysis, presence of visceral
disease (HR 4.8, 95 % CI 1.026–22.465, p = 0.0015),
presence of PSA response (HR 0.104, 95 % CI 0.025–
0.387, p = 0.0001), short (<10 months) response to prior
ADT (HR 2.656, 95 % CI 1.061–6.648, p = 0.0336), ECOG
2 or above (HR 4.907, 95 % CI 1.648–14.612, p = 0.0001),
and low hemoglobin level (HR 2.696, 95 % CI 0.912–
7.7971, p = 0.0409) were determinants of OS. Presence of
PSA response (HR 0.186, 95 % CI 0.079–0.439, p < 0.0001)
and presence of visceral disease (HR 5.891, 95 % CI 1.43–
24.267, p = 0.0126) were determinants of PFS.
Post-chemo group
In multivariate analysis, presence of PSA response (HR
0.213, 95 % CI 0.076–0.592, p = 0.0001), Gleason score
of ≥ 8 (HR 2.658, 95 % CI 1.13–6.251, p = 0.0186) and
PSA-DT of < 2 months (HR 3.006, 95 % CI 1.278–7.07,
p = 0.0289) were determinants of OS, while presence of
PSA response (HR 0.403, 95 % CI 0.203–0.797, p =
0.0007) was a determinant of PFS (Table 5).
Discussion
In the current study, we reported the efficacy and tox-
icity of AA in mCRPC patients from an unselected pa-
tient population in a non-trial setting. The inclusion of
all AA-treated patients in all public oncology centers
during a defined period serves to provide a representa-
tive picture of the efficacy of AA in clinical service set-
ting. The clinical efficacy, notably the OS and PFS, and
tolerability of AA in our post-chemo patients was similar
to that of the COU-AA-301 study (Table 6), thus repro-
ducing the efficacy of AA in the post-chemotherapy
setting. However, unexpectedly, the median OS of
chemo-naïve patients in our cohort (of 18.1 months)
was remarkably much shorter than that reported in
COU-AA-302 study (of 34.7 months). It is noted that
our chemo-naïve patients with visceral disease, the pa-
tient group that was excluded in the COU-AA-302
study, had significantly inferior survival. If this small
subset of poor-prognosis patients was excluded, the OS
and PFS of the chemo-naïve patients without visceral
metastases were still unfavorable, being similar to the
whole group. Thus inclusion of patients with visceral
disease in our study cannot entirely explicate the un-
favorable survival outcome of chemo-naïve patients. It
is also unlikely that the infrequency of post-AA treat-
ment contributes to the unfavorable survival, as the
subset of patients given post-AA treatment did not
have more favorable survival than those without in
the multivariate analysis. We postulate that the infer-
ior survival outcome of our chemo naïve patients
could be attributable to a relatively high tumor bur-
den in this patient cohort, compared to that in the
COU-302 study. This is supported by a higher base-
line PSA level (median: 212 ug/l) in our patients as





Median duration of AA treatment,
month (range)
6.8 (0.6–21.5) 7.1 (0.5–25.0)
PSA response (%)
≥50 % PSA decline from baseline 36 (62.1) 26 (50.0)
≥90 % PSA decline from baseline 16 (27.6) 8 (15.4)
Median time to PSA nadir, month (range) 3.1 (0.9–15.0) 2.8 (0.5–15.3)
PSA flare (%)
No. of patients 17 (29.3) 15 (28.8)
Presence of eventual PSA response
(≥50 % PSA decline from baseline)
12 (70.6) 10 (66.7)
Pain alleviation during or after AAa (%) 11 (57.9 %) 11 (68.8 %)
Reasons of discontinuing AA (%)
Disease progression 24 (41.4) 36 (69.2)
Treatment-related complication 3 (5.2) 1 (1.9)
Patient’s decision 3 (5.2) 2 (3.8)
Unknown 1 (1.7) 0
Continuation of AA beyond PD
No. of patients (%) 13 (22.4) 18 (34.6)
Median time, month (range) 2.8 (1.0–5.8) 2.0 (1.2–16.2)
Subsequent therapy after PD (%)
Docetaxel 5 (8.6) 2 (3.8)
Cabazitaxel 2 (3.4) 7 (13.5)
Mitoxantrone 0 1 (1.9)
Ketoconazole 0 1 (1.9)
Abbreviations: PSA prostate specific antigen, AA abiraterone acetate, PD
disease progression
aWithdrawal or reduction of level II or III analgesics according to WHO
analgesics ladder
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compared to that in the COU-AA-302 study (median:
42 ug/l). Besides, the inclusion of chemo-naïve pa-
tients with poor prognostic features in our study
could also account for the unsatisfactory survival re-
sults. For example, our patient cohort included symp-
tomatic patients (only asymptomatic or mildly
symptomatic patients were included in COU-AA-302
study) and patients with ECOG 2 (patients with
ECOG 2 or above were excluded in COU-AA-302
study), and a higher proportion of elderly patients:
63.8 % of patients were age above 75 in our cohort,
compared to 34 % in COU-AA-302 study.
It is worth noting that despite the somewhat disap-
pointing survival outcome in chemo-naïve patients
treated with AA; nearly 60 % of symptomatic patients
had pain alleviation. In fact, such a rate of pain con-
trol is similar to that in post-chemo patients, and was
also comparable to that in the COU-AA-301 study,
Fig. 1 The overall survival for mCRPC patients with (post-chemo) or without prior chemotherapy (chemo-naïve) treated with AA
Fig. 2 The progression-free survival for mCRPC patients with (post-chemo) or without prior chemotherapy (chemo-naïve) treated with AA
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despite the pain assessment tools were not identical
between ours and the pivotal studies (Table 6). To
our knowledge, the present study is the first one to
report on efficacy of pain control for symptomatic
chemo-naïve patients with AA.
While data on efficacy of AA on chemo-naive patients
with visceral metastases or symptomatic disease is being
awaited, the present study suggests that patients with
high tumor burden, visceral metastases and symptomatic
disease may have inferior outcome with AA. An
Fig. 3 The overall survival for a chemo-naïve and b post-chemo mCRPC patients with or without visceral disease, and the progression-free survival for
c chemo-naïve and d post-chemo mCRPC patients with or without visceral disease
Table 3 Adverse events during treatment
Chemo-naïve (%) Post-chemo (%)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Peripheral edema 6 (10.3) 0 3 (5.2) 0 2 (3.8) 1 (1.9) 0 0
Elevation of liver enzymes 7 (12.1) 0 0 0 3 (5.8) 0 1 (1.9) 0
Hypokalemia 15 (25.9) 1 (1.7) 2 (3.4) 0 9 (17.3) 2 (3.8) 2 (3.8) 0
Hypertension 9 (15.5) 7 (12.1) 4 (6.9) 0 17 (32.7) 3 (5.8) 3 (5.8) 0
Fatigue 1 (1.7) 0 0 0 1 (1.9) 0 0 0
Arthralgia 0 0 0 0 1 (1.9) 0 0 0
Diarrhoea 0 0 0 0 1 (1.9) 0 0 0
Dyspepsia 1 (1.7) 0 0 0 0 0 0 0
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exploratory analysis of the visceral disease subgroup in
the COU-AA-301 study [6] has demonstrated that the
presence of visceral disease is prognostic but not pre-
dictive of the response to AA [12]. Nonetheless, there
are growing evidences that the efficacies of therapies are
different in chemo-naïve patients and post-chemo pa-
tients [13]. In contrast, the presence of symptomatic or
visceral metastasis did not confer inferior clinical out-
come to docetaxel-based chemotherapy, as reflected by
the subgroup analysis in the TAX 327 study [14]. With
the lack of randomized trial specifically addressing AA
efficacy in chemo-naïve patients with visceral or symp-
tomatic disease, the practice of advocating AA in this
particular subgroup should be further scrutinized in the
context of clinical trial. Indeed, the data in the present
study may support a treatment paradigm of offering AA
to mCRPC patients with relatively low tumor burden,
and chemotherapy for patients with high tumor burden,
and visceral disease. Besides, based on the present
study’s data, patients with symptomatic disease may also
be considered for AA to help pain control, though the
survival outcome is less than favorable.
The achievement of PSA response after AA as a
favorable prognosticator is in consistency with prior
experience based on the data from COU-AA-302 and
301 studies, in which substantial correlation between
survival and PSA kinetics was established [15]. Con-
versely, the absence of PSA response could potentially
be used as a biomarker to select patients earlier for alter-
native or additional treatment in future clinical trial.
In our study, more than half of patients with initial
PSA flare had ultimate PSA response to AA and, fur-
thermore, there was no substantial difference in clinical
outcome in patients with or without PSA flare. Conse-
quently, in view of the not uncommon occurrence of
PSA flare in some patients, PSA response is better
determined at least 12 weeks after treatment, as recom-
mended by the PCWG-2 and the premature discontinu-
ation of AA when encountering initial PSA flare is not
suggested [11]. In contrast, the practice of further con-
tinuation of AA beyond progression is not advised as the
meta-analysis in our study has exemplified that there
was no additional enhancement of survival with ex-
tended AA.
Short duration of response to prior ADT (<10 months)
was associated with an unfavorable survival in chemo-
naïve patients with AA in this study. Our finding sub-
stantiates the other reports that the short response to
Table 4 Univariate and multivariate analysis of overall survival and progression-free survival – Chemo-naive group
Factors Univariate analysis Multivariate analysis
Progression-free survival Overall survival Progression-free survival Overall survival
P value HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value HR 95 % CI
Time from ADT to CRPC
(<10 vs≥ 10 months)
0.0306 2.191 1.057–4.542 0.0002 4.566 1.913–10.898 0.816 1.104 0.49–2.489 0.0336 2.656 1.061–6.648
ECOG (2–3 vs 0–1) 0.273 1.51 0.718–3.176 0.0034 3.392 1.426–8.071 N.A. N.A. N.A. 0.0001 4.907 1.648–14.612
Age (<75 vs ≥75) 0.2687 0.664 0.319–1.381 0.8875 1.068 0.43–2.653 N.A. N.A. N.A. N.A. N.A. N.A.
Gleason score ( ≥8 vs <8) 0.9539 1.023 0.471–2.225 0.9549 0.973 0.376–2.515 N.A. N.A. N.A. N.A. N.A. N.A.
Visceral met (yes vs no) 0.0088 4.7 1.313–16.82 0.0007 6.907 1.881–25.357 0.0126 5.891 1.43–24.267 0.0015 4.8 1.026–22.465
Symptomatic (yes vs no) 0.6554 1.183 0.565–2.476 0.1193 1.966 0.826–4.682 N.A. N.A. N.A. N.A. N.A. N.A.
PSA doubling time
(<2 months vs ≥2 months)
0.1667 1.651 0.804–3.393 0.4794 1.573 0.568–3.319 N.A. N.A. N.A. N.A. N.A. N.A.
Baseline PSA
( ≥200 vs <200 ug/l )
0.0014 3.26 1.513–7.021 0.0365 2.558 1.028–6.364 0.0686 2.15 0.933–4.954 0.6339 1.313 0.428–4.038
Baseline ALP
( ≥120 vs <120 IU/l)
0.1464 1.69 0.825–3.466 0.0535 2.459 0.987–6.13 N.A. N.A. N.A. N.A. N.A. N.A.
Baseline Hb
(<12 vs ≥12 g/dl)
0.1618 1.676 0.805–3.488 0.023 2.712 1.109–6.631 N.A. N.A. N.A. 0.0409 2.696 0.912–7.7971
PSA response (yes vs no) <0.0001 0.135 0.061–0.299 0.0001 0.176 0.067–0.459 <0.0001 0.186 0.079–0.439 0.0001 0.104 0.025–0.387
PSA flare (yes vs no) 0.0623 0.471 0.209–1.06 0.0652 0.373 0.125–1.111 N.A. N.A. N.A. N.A. N.A. N.A.
Continuation of AA beyond
progression (yes vs no)
N.A. N.A. N.A. 0.9863 0.992 0.382–2.574 N.A. N.A. N.A. N.A. N.A. N.A.
Post-AA treatment
(yes vs no)
N.A. N.A. N.A. 0.3604 0.51 0.117–2.219 N.A. N.A. N.A. N.A. N.A. N.A.
Abbreviations: HR hazard ratio, 95 % CI 95 % confidence interval, ADT androgen deprivation treatment, CRPC castration-resistant prostate cancer, ECOG Eastern
Cooperative Oncology Group, Symptomatic presence of pain prior abiraterone acetate and require WHO level II or above analgesics, PSA prostate-specific antigen,
ALP alkaline phosphatase, Hb haemoglobin, PSA response, ≥50 % drop of PSA from baseline, PSA flare, PSA upsurge but not to the extent of biochemical progression,
AA abiraterone acetate, N.A. not applicable
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ADT was associated with poorer efficacy with AR-
pathway targeted therapy, in particular AA, in mCRPC
patients [16, 17]. And this echoed the statement made in
the latest European consensus that short duration of re-
sponse to ADT could be used to identify patients with
increased risk of primary resistance to AR-pathway tar-
geted agents [18].
Limitations existed in the present study, which include
the typical shortcomings of retrospective study such as
under-reporting of adverse events, incompleteness of
data collection and selection bias etc. However, we con-
sider these limitations would not affect the ability to
capture the survival outcome of AA in this study. And
the inadequate sample size, difference in follow-up
Table 5 Univariate and multivariate analysis of overall survival and progression-free survival – Post-chemo group
Factors Univariate analysis Multivariate analysis
Progression-free survival Overall survival Progression-free survival Overall survival
P value HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value HR 95 % CI
Time from ADT to CRPC
(<10 vs≥ 10 months)
0.4867 0.788 0.4–1.549 0.0649 0.476 0.213–1.063 N.A. N.A. N.A. N.A. N.A. N.A.
ECOG (2–3 vs 0–1) 0.4084 0.648 0.229–1.832 0.7205 1.248 0.371–4.198 N.A. N.A. N.A. N.A. N.A. N.A.
Age (<75 vs ≥75) 0.2988 0.649 0.285–1.478 0.0136 0.303 0.103–0.886 N.A. N.A. N.A. 0.3685 0.559 0.155–2.008
Gleason score (≥8 vs <8) 0.0528 1.922 0.98–3.77 0.0236 2.559 1.117–5.846 N.A. N.A. N.A. 0.0186 2.658 1.13–6.251
Visceral metastasis (yes vs no) 0.1972 1.793 0.727–4.42 0.3474 1.592 0.598–4.237 N.A. N.A. N.A. N.A. N.A. N.A.
Symptomatic (yes vs no) 0.7678 1.112 0.549–2.253 0.637 1.227 0.524–2.87 N.A. N.A. N.A. N.A. N.A. N.A.
PSA doubling time
(<2 months vs ≥2 months)
0.251 1.459 0.762–2.794 0.0319 2.337 1.054–5.18 N.A. N.A. N.A. 0.0289 3.006 1.278–7.07
Baseline PSA
(≥200 vs <200 ug/l)
0.3603 1.356 0.703–2.615 0.422 1.367 0.636–2.938 N.A. N.A. N.A. N.A. N.A. N.A.
Baseline ALP
(≥120 vs <120 IU/l)
0.6113 0.848 0.448–1.605 0.7189 1.151 0.536–2.471 N.A. N.A. N.A. N.A. N.A. N.A.
Baseline Hb
(<12 vs ≥12 g/dl)
0.2146 1.538 0.774–3.056 0.0811 2.143 0.892–5.149 N.A. N.A. N.A. N.A. N.A. N.A.
PSA response (yes vs no) 0.0007 0.336 0.174–0.648 0.0001 0.207 0.089–0.493 0.0007 0.403 0.203–0.797 0.0001 0.213 0.076–0.592
PSA flare (yes vs no) 0.0130 0.38 0.172–0.838 0.2531 0.609 0.257–1.438 0.0987 0.505 0.222–1.149 N.A. N.A. N.A.
Refractory to prior
chemotherapy (yes vs no)
0.3883 1.376 0.663–2.857 0.2234 1.659 0.729–3.773 N.A. N.A. N.A. N.A. N.A. N.A.
Continuation of AA beyond
progression (yes vs no)
N.A. N.A. N.A. 0.064 0.481 0.218–1.060 N.A. N.A. N.A. N.A. N.A. N.A.
Post-AA treatment (yes vs no) N.A. N.A. N.A. 0.3224 0.65 0.275–1.535 N.A. N.A. N.A. N.A. N.A. N.A.
Abbreviations: HR hazard ratio, 95 % CI 95 % confidence interval, ADT androgen deprivation treatment, CRPC castration-resistant prostate cancer, ECOG Eastern
Cooperative Oncology Group, Symptomatic presence of pain prior abiraterone acetate and require WHO analgesic class II or III analgesics, PSA prostate-specific
antigen, ALP alkaline phosphatase, Hb haemoglobin, PSA response, ≥50 % drop of PSA from baseline, PSA flare PSA upsurge but not to the extent of biochemical
progression, AA abiraterone acetate, N.A. not applicable
Table 6 Clinical outcome in the present study and the AA pivotal trial
Survival outcome Present study (Chemo-naïve) COU-AA-302 study Present study (Post-chemo) COU-AA-301 study
Median OS, months 18.1 34.7 15.5 15.8
Median PFS, months 6.7a 16.5b 6.4a 8.5c
5.6d
PSA response, % 62.1 62 50.0 29
Pain control, % 57.9e – 68.8e 44f
Abbreviations: OS overall survival, PFS progression-free survival, PSA response ≥50 % decline of PSA from baseline, PSA prostate-specific antigen




eWithdrawal or reduction of level II or III analgesics according to WHO analgesics ladder
fReduction of ≥30 % in the brief pain inventory-short form (BPI-SF) worst pain intensity score over the last 24 h observed at two consecutive evaluations 4 weeks
apart without any increase in analgesic usage score; only patients experiencing a pain score ≥4 at baseline were included
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protocols and the policy of post-AA treatment among
different hospitals were the other weakness of the
current study. Of note, unlike prospective study, regular
imaging was not mandatory in our study and this could
deprive some patients from other life-prolonging treat-
ment earlier before any clinical or biochemical progression
existed. Finally, the follow-up time for the chemo-naive
group is comparatively inadequate and the inferior out-
come in this group may not be the ultimate result. Our
group will plan for another follow-up study in the future.
Conclusions
The present study reported the unanticipated short sur-
vival after AA in chemo-naïve patient outside clinical
trial setting. The overall survival was particularly short
in those with visceral diseases, and further clinical trial
for AA in this subgroup of patients is warranted. In con-
trast, AA was well tolerated and efficacious in mCRPC
patients with prior chemotherapy. AA resulted in com-
parable pain control in both groups of patients. PSA re-
sponse, in particular present within the first 3 months
after AA, could serve as a prognostic biomarker for sur-
vival outcome and may have a potential role in selecting
patients for additional or alternative treatment earlier in
future clinical trial.
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